PPARδ activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference

Archives of Physiology and Biochemistry

Volumn 120, Issue 1, 2014, Pages 12-21

  Feng, Yuan Z ^a   Nikolić, Nataša ^a   Bakke, Siril S ^a   Boekschoten, Mark V ^b   Kersten, Sander ^b   Kase, Eili T ^a   Rustan, Arild C ^a   Thoresen, G Hege ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Cholesterol biosynthesis; Global gene analysis; Glucose metabolism; Mitochondrial oxidative capacity; Oleic acid

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE; TRANSCRIPTOME; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ARTICLE; BIOSYNTHESIS; BLOOD; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; ENZYME SPECIFICITY; HUMAN; METABOLISM; MIDDLE AGED; MITOCHONDRION; OXIDATION REDUCTION REACTION; SKELETAL MUSCLE;

CHOLESTEROL; FATTY ACIDS; GLUCOSE; HUMANS; INSULIN; MIDDLE AGED; MITOCHONDRIA; MUSCLE FIBERS, SKELETAL; OLEIC ACID; OXIDATION-REDUCTION; PPAR DELTA; SUBSTRATE SPECIFICITY; THIAZOLES; TRANSCRIPTOME;

EID: 84893146305     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2013.829105     Document Type: Article

References (50)

1. Aas V, Bakke SS, Feng YZ, et al. (2013). Are cultured human myotubes far from home? Cell Tissue Res. Epub ahead of print.
2. Aas V, Rokling-Andersen MH, Kase ET, et al. (2006). Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells. J Lipid Res, 47:366-74.
3. Badin PM, Loubiere C, Coonen M, et al. (2012). Regulation of skeletal muscle lipolysis and oxidative metabolism by the co-lipase CGI-58. J Lipid Res, 53:839-48.
4. Bakke SS, Moro C, Nikolic N, et al. (2012). Palmitic acid follows a different metabolic pathway than oleic acid in human skeletal muscle cells; lower lipolysis rate despite an increased level of adipose triglyceride lipase. Biochim Biophys Acta, 1821:1323-33.
5. Bays HE, Schwartz S, Littlejohn 3rd T, et al. (2011). MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab, 96:2889-97.
6. Bezaire V, Bruce CR, Heigenhauser GJ, et al. (2006). Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: essential role in fatty acid oxidation. Am J Physiol Endocrinol Metab, 290:E509-15.
7. Boschmann M, Engeli S, Moro C, et al. (2010). LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance. J Clin Endocrinol Metab, 95:1634-43.
8. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem, 72:248-54.
9. Brunmair B, Staniek K, Dorig J, et al. (2006). Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia, 49:2713-22.
10. Campbell SE, Tandon NN, Woldegiorgis G, et al. (2004). A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem, 279: 36235-41.
11. Ciocoiu CC, Nikolic N, Nguyen HH, et al. (2010). Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516. Eur J Med Chem, 45:3047-55.
12. Cresser J, Bonen A, Chabowski A, et al. (2010). Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers. Am J Physiol Regul Integr Comp Physiol, 299:R470-9.
13. de Lange P, Lombardi A, Silvestri E, et al. (2008). Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle. PPAR Res, 2008:172676.
14. Debard C, Cozzone D, Ricard N, et al. (2006). Short-term activation of peroxysome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients. J Mol Med (Berl), 84:747-52.
15. Dimopoulos N, Watson M, Green C, et al. (2007). The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett, 581:4743-8.
16. Dressel U, Allen TL, Pippal JB, et al. (2003). The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol, 17:2477-93.
17. Ehrenborg E, Krook A. (2009). Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor. Pharmacol Rev, 61:373-93.
18. Fritz T, Kramer DK, Karlsson HK, et al. (2006). Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab Res Rev, 22:492-8.
19. Furnsinn C, Willson TM, Brunmair B. (2007). Peroxisome proliferatoractivated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia, 50:8-17.
20. Gaster M, Kristensen SR, Beck-Nielsen H, et al. (2001). A cellular model system of differentiated human myotubes. APMIS, 109:735-44.
21. Gaster M, Rustan AC, Aas V, et al. (2004). Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin: evidence from cultured myotubes. Diabetes, 53:542-8.
22. Hancock CR, Han DH, Chen M, et al. (2008). High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci USA, 105:7815-20.
23. Hessvik NP, Bakke SS, Fredriksson K, et al. (2010). Metabolic switching of human myotubes is improved by n-3 fatty acids. J Lipid Res, 51: 2090-104.
24. Houmard JA. (2008). Intramuscular lipid oxidation and obesity. Am J Physiol - Regulatory Integrative and Comparative Physiology, 294: R1111-16.
25. Jans A, Konings E, Goossens GH, et al. (2012). PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. Am J Clin Nutr, 95:825-36.
26. Jucker BM, Yang D, Casey WM, et al. (2007). Selective PPAR agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: An in vivo magnetic resonance spectroscopy study. Am J Physiol - Endocrinology and Metabolism, 293:E1256-64.
27. Kiens B. (2006). Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiolog Rev, 86:205-43.
28. Kleiner S, Nguyen-Tran V, Bare O, et al. (2009). PPARagonism activates fatty acid oxidation via PGC-1a but does not increase mitochondrial gene expression and function. J Biol Chem, 284: 18624-33.
29. Kramer DK, Al-Khalili L, Guigas B, et al. (2007). Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem, 282:19313-20.
30. Kramer DK, Al-Khalili L, Perrini S, et al. (2005). Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes, 54: 1157-63.
31. Lee CH, Olson P, Hevener A, et al. (2006). PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA, 103: 3444-9.
32. Leibowitz MD, Fievet C, Hennuyer N, et al. (2000). Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett, 473: 333-6.
33. Luquet S, Lopez-Soriano J, Holst D, et al. (2003). Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J, 17:2299-301.
34. Nikolic N, Skaret Bakke S, Tranheim Kase E, et al. (2012). Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro model of exercise. PLoS One, 7:e33203.
35. Oliver Jr WR, Shenk JL, Snaith MR, et al. (2001). A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA, 98:5306-11.
36. Patti ME, Corvera S. (2010). The role of mitochondria in the pathogenesis of type 2 diabetes. Endo Rev, 31:364-95.
37. Phielix E, Mensink M. (2008). Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav, 94:252-8.
38. Randle PJ, Garland PB, Hales CN, et al. (1963). The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1:785-9.
39. Riserus U, Sprecher D, Johnson T, et al. (2008). Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 57:332-9.
40. Scarpulla RC. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev, 88:611-38.
41. Sprecher DL, Massien C, Pearce G, et al. (2007). Triglyceride:highdensity lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol, 27:359-65.
42. Spriet LL, Tunstall RJ, Watt MJ, et al. (2004). Pyruvate dehydrogenase activation and kinase expression in human skeletal muscle during fasting. J Appl Physiol, 96:2082-7.
43. Staiger H, Haas C, Machann J, et al. (2009). Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-and is of metabolic relevance in humans. Diabetes, 58:579-89.
44. Storey JD, Tibshirani R. (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci USA, 100:9440-5.
45. Subramanian A, Tamayo P, Mootha VK, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA, 102: 15545-50.
46. Tanaka T, Yamamoto J, Iwasaki S, et al. (2003). Activation of peroxisome proliferator-activated receptor induces fatty acid betaoxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA, 100:15924-9.
47. Terada S, Wicke S, Holloszy JO, et al. (2006). PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle. Am J Physiol, Endocrin Metabol, 290:E607-11.
48. Wang YX, Lee CH, Tiep S, et al. (2003). Peroxisome-proliferatoractivated receptor delta activates fat metabolism to prevent obesity. Cell, 113:159-70.
49. Wang YX, Zhang CL, Yu RT, et al. (2004). Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol, 2:e294.
50. Wensaas AJ, Rustan AC, Lovstedt K, et al. (2007). Cell-based multiwell assays for the detection of substrate accumulation and oxidation. J Lipid Res, 48:961-7.